Virax Biolabs Group Limited (VRAX)
(Delayed Data from NSDQ)
$0.78 USD
-0.01 (-0.78%)
Updated Aug 8, 2025 03:40 PM ET
After-Market: $0.79 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRAX 0.78 -0.01(-0.78%)
Will VRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRAX
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
VRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VRAX
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial ...
Virax Biolabs (VRAX) Faces Nasdaq Compliance Challenge | VRAX Stock News
Virax Biolabs receives noncompliance notice from Nasdaq
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price ...
Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule